Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer

NCT00820547 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00820547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00820547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2019
Enrollment
100 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer